Idhifa did not meet the primary endpoint of overall survival in the IDHENTIFY study to treat acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation.- BMS

-Bristol Myers Squibb announced that the Phase III IDHENTIFY study evaluating Idhifa (enasidenib) plus best supportive care (BSC) versus conventional care regimens, which include best supportive care (BSC) only, azacitidine plus BSC, low-dose cytarabine plus BSC or intermediate-dose cytarabine plus BSC, did not meet the primary endpoint of overall survival (OS) in patients with relapsed or refractory acute myeloid leukemia (R/R AML) with an isocitrate dehydrogenase-2 (IDH2) mutation The safety profile of Idhifa was consistent with previously reported findings. The company will complete a full evaluation of the IDHENTIFY data and work with investigators to present detailed results at a future medical meeting.